US equities
|
TSLA
$391.62
▲+5.21%
MU
$903.70
▲+2.98%
NVDA
$216.00
▲+2.39%
META
$630.56
▼-1.88%
SPCX
$146.90
▼-0.40%
AAPL
$343.91
▼-1.10%
MSFT
$532.60
▲+1.54%
INTC
$90.47
▲+4.04%
TSLA
$391.62
▲+5.21%
MU
$903.70
▲+2.98%
NVDA
$216.00
▲+2.39%
META
$630.56
▼-1.88%
SPCX
$146.90
▼-0.40%
AAPL
$343.91
▼-1.10%
MSFT
$532.60
▲+1.54%
INTC
$90.47
▲+4.04%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Vivos Therapeutics, Inc. - Common Stock
(NQ:
VVOS
)
0.1313
-0.0024 (-1.80%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 26, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Vivos Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
Next >
SOD Sciences Welcomes Vivos Therapeutics as Strategic Investor and Partner in the ReBalU Primed Cell Test
October 20, 2026
Partnership unites the ReBalU Protocol, Vivos's sleep platform, and a new test for cells primed for chronic disease, reaching nearly 500,000 chronic‑disease patients
From
SOD SCIENCES INC.
Via
ACCESS Newswire
New to The Street Broadcasting Today at 6:30 PM EST on Bloomberg Television Across the U.S., Latin America and MENA-Featuring FreeCast (NASDAQ: CAST), Metaterra Holdings (MTHI) and SafeSpace Global (SGCC)
August 29, 2026
From
New to The Street
Via
ACCESS Newswire
New to The Street to Broadcast Tonight on Bloomberg at 6:30 PM EST - Show #744 Featuring Virtuix Holdings (NASDAQ:VTIX), Neonc Technologies Holdings (NASDAQ:NTHI), Medicus Pharma (NASDAQ:MDCX), YY Group Holding (NASDAQ:YYGH), and Vivos Therapeutics
April 18, 2026
Via
ACCESS Newswire
Vivos Therapeutics Inc. (NASDAQ: VVOS) Near the Top of Equities by Percentage Gain on 11/29
November 29, 2023
Via
Investor Brand Network
New to The Street to Broadcast on Fox Business on Monday, April 13, Featuring Virtuix Holdings (NASDAQ:VTIX), Medicus Pharma (NASDAQ:MDCX), YY Group Holdings (NASDAQ:YYGH), Vivos Therapeutics (NASDAQ:VVOS), and Stardust Power (NASDAQ:SDST)
April 11, 2026
Via
ACCESS Newswire
New to The Street Broadcasts Show #740 on Bloomberg Television at 6:30 PM EST Featuring Medicus (MDCX), Acme Markets- Canton Foundation, Alpha Ton Capital (ATON), and Virtuix Holdings (NASDAQ:VTIX)
March 28, 2026
Via
ACCESS Newswire
New to The Street to Broadcast Executive Leadership Interviews Featuring Medicus Pharma Ltd. (NASDAQ:MDCX), CitroTech (NYSE:CITR), Vivos Therapeutics, Inc. (NASDAQ:VVOS), and Virtuix Holdings ($VTIX) on Bloomberg Television Tonight at 6:30 PM EST
February 28, 2026
Via
ACCESS Newswire
New to The Street to Broadcast Executive Leadership Interviews Tonight at 6:30 PM EST on Bloomberg Television Across the U.S., MENA and Latin America
February 21, 2026
Via
ACCESS Newswire
New to The Street to Broadcast Show #726 on Bloomberg at 6:30 PM EST Featuring Vivos Therapeutics (NASDAQ:VVOS), Aeries Technology (NASDAQ:AERT), Virtuix Holdings (NASDAQ:VTIX), and Stardust Power (NASDAQ:SDST)
February 14, 2026
Via
ACCESS Newswire
VIVOS Therapeutics, Inc. ($VVOS) Signs 12-Part Media Series with New to The Street
February 05, 2026
Via
ACCESS Newswire
Water Tower Research Publishes Initiation of Coverage Report on Vivos Therapeutics, Inc., “New Strategic Model & Key Regulatory Milestones Provide Revenue Tailwind”
December 10, 2024
December 10, 2024, ST. PETERSBURG, FL – Water Tower Research (www.watertowerresearch.com) has published an Initiation of Coverage Report on Vivos Therapeutics, Inc. (NASDAQ: VVOS) titled, “New...
Via
TheNewswire.com
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces AMA Issues CPT Codes, Coverage for Vivos CARE Oral Medical Devices
October 08, 2024
Via
Investor Brand Network
TinyGemsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces $4.3M Registered Direct Offering
September 19, 2024
Via
Investor Brand Network
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Awarded First-Ever FDA Clearance for Pediatric Treatment of Sleep Apnea, Snoring
September 18, 2024
Via
Investor Brand Network
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Releases Report on Q2 2024 Financial Results, Operational Update
August 15, 2024
Via
Investor Brand Network
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Plans Release of Q2 2024 Financial Results, Conference Call
August 14, 2024
Via
Investor Brand Network
TinyGemsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Reports Results of Seven-Month Provider-Based Marketing and Distribution Model Pilot
June 27, 2024
Via
Investor Brand Network
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Strategic Alliance, Private Equity Investment
June 12, 2024
Via
Investor Brand Network
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Releases Q1 2024 Financial Report, Operational Update
May 15, 2024
Via
Investor Brand Network
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Schedules Release of Q1 2024 Results, Conference Call
May 14, 2024
Via
Investor Brand Network
TinyGemsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) CEO Discusses Medicare Reimbursement Approval for CARE Oral Medical Devices in Proactive Interview
April 10, 2024
Via
Investor Brand Network
Topics
Product Recall
TinyGemsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Achieves Milestone with CARE Oral Medical Devices Gaining Approval for Medicare Reimbursement
April 09, 2024
Via
Investor Brand Network
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Schedules Release of Q4 and FY 2023 Results, Conference Call
March 28, 2024
Via
Investor Brand Network
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Exercise of Warrants for ~$4M
February 15, 2024
Via
Investor Brand Network
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) CEO Highlights Favorable Market Developments Creating New Opportunities
February 13, 2024
Via
Investor Brand Network
Topics
Product Recall
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Notes Key Market Developments Resulting in Growth Opportunities
February 06, 2024
Via
Investor Brand Network
Topics
Product Recall
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Reports Record Numbers Following First-Ever FDA 510(k) Clearance of Proprietary Oral Medical Devices
January 08, 2024
Via
Investor Brand Network
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) to Host Pioneering Conference for Women in Medical, Dental Sectors
December 11, 2023
Via
Investor Brand Network
Black Swan: this small cap surged over 1000% last week
December 04, 2023
Vivos Therapeutics experienced a rare 'black swan' event, surging over 1000% in a single day following breaking news, here's how to look at VVOS stock now
Via
MarketBeat
InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) CEO Discussed ‘Breakthrough’ FDA Clearance in Proactive Interview
November 30, 2023
Via
Investor Brand Network
< Previous
1
2
3
4
Next >
